- Home
- WETO vs TCRX Comparison
WETO vs TCRX Comparison
Compare WETO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETO
- TCRX
- Stock Information
- Founded
- WETO 2019
- TCRX 2018
- Country
- WETO China
- TCRX United States
- Employees
- WETO N/A
- TCRX N/A
- Industry
- WETO
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- WETO
- TCRX Health Care
- Exchange
- WETO NYSE
- TCRX Nasdaq
- Market Cap
- WETO 81.4M
- TCRX 67.9M
- IPO Year
- WETO 2025
- TCRX 2021
- Fundamental
- Price
- WETO $3.90
- TCRX $1.44
- Analyst Decision
- WETO
- TCRX Strong Buy
- Analyst Count
- WETO 0
- TCRX 6
- Target Price
- WETO N/A
- TCRX $9.83
- AVG Volume (30 Days)
- WETO 22.1K
- TCRX 520.8K
- Earning Date
- WETO 01-01-0001
- TCRX 05-12-2025
- Dividend Yield
- WETO N/A
- TCRX N/A
- EPS Growth
- WETO N/A
- TCRX N/A
- EPS
- WETO N/A
- TCRX N/A
- Revenue
- WETO $6,326,827.00
- TCRX $2,816,000.00
- Revenue This Year
- WETO N/A
- TCRX $47.30
- Revenue Next Year
- WETO N/A
- TCRX $74.30
- P/E Ratio
- WETO N/A
- TCRX N/A
- Revenue Growth
- WETO N/A
- TCRX N/A
- 52 Week Low
- WETO $3.10
- TCRX $1.02
- 52 Week High
- WETO $4.28
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- WETO N/A
- TCRX 49.74
- Support Level
- WETO N/A
- TCRX $1.02
- Resistance Level
- WETO N/A
- TCRX $1.36
- Average True Range (ATR)
- WETO 0.00
- TCRX 0.16
- MACD
- WETO 0.00
- TCRX 0.05
- Stochastic Oscillator
- WETO 0.00
- TCRX 77.78
About WETO WEBUS INTERNATIONAL LIMITED
Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.